Cancer Immunology Immunotherapy · 2024 · 12 citations · 15 references
MedicineOncologyPharmacologyCancer ImmunologyImmunotherapyTumor ImmunologyAntitumor T Cell ResponsesCancer ImmunotherapyImmunotherapy For Solid TumorsImmunotherapy SafetyPharmacodynamics Of ImmunotherapiesPharmacokinetics Of Monoclonal AntibodiesBispecific Antibody ConjugatesBispecific Antibody PharmacodynamicsCd3-directed Bispecific AntibodiesHla-restricted ImmunotherapyHuman Leukocyte Antigen-g ExpressionTumor Antigen-based ImmunotherapyTumor-associated Antigen TargetingTumor-associated Cytokines
BACKGROUND: JNJ-78306358 is a bispecific antibody that redirects T cells to kill human leukocyte antigen-G (HLA-G)-expressing tumor cells. This dose escalation study evaluated the safety, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of JNJ-78306358 in patients with advanced solid tumors. METHODS: Adult patients with metastatic/unresectable solid tumors with high prevalence of HLA-G expression were enrolled. Dose escalation was initiated with once-weekly subcutaneous administration with step-up dosing to mitigate cytokine release syndrome (CRS). RESULTS: Overall, 39 heavily pretreated patients (colorectal cancer: n = 23, ovarian cancer: n = 10, and renal cell carcinoma: n = 6) were dosed in 7 cohorts. Most patients (94.9%) experienced ≥ 1 treatment-emergent adverse events (TEAEs); 87.2% had ≥ 1 related TEAEs. About half of the patients (48.7%) experienced CRS, which were grade 1/2. Nine patients (23.1%) received tocilizumab for CRS. No grade 3 CRS was observed. Dose-limiting toxicities (DLTs) of increased transaminases, pneumonitis and recurrent CRS requiring a dose reduction were reported in 4 patients, coinciding with CRS. No treatment-related deaths reported. No objective responses were noted, but 2 patients had stable disease > 40 weeks. JNJ-78306358 stimulated peripheral T cell activation and cytokine release. Anti-drug antibodies were observed in 45% of evaluable patients with impact on exposure. Approximately half of archival tumor samples (48%) had expression of HLA-G by immunohistochemistry. CONCLUSION: JNJ-78306358 showed pharmacodynamic effects with induction of cytokines and T cell activation. JNJ-78306358 was associated with CRS-related toxicities including increased transaminases and pneumonitis which limited its dose escalation to potentially efficacious levels. Trial registration number ClinicalTrials.gov (No. NCT04991740).
15
Mark R. Middleton, Cheryl McAlpine, Victoria K. Woodcock et al. · Clinical Cancer Research · 2020 · 272 citations · Full text
Life Sciences, Immunology, Oncology +17
HLA-G expression in human ovarian carcinoma counteracts NK cell function
Aifen Lin, Wei‐Hua Yan, Heping Xu et al. · Annals of Oncology · 2007 · 100 citations
Life Sciences, Immunology, Oncology +12